FOLH1 and neoplasm: A phase I dose-escalation trial of 225Ac-J591, an α-emitting anti-PSMA monoclonal antibody, demonstrated preliminary efficacy in 32 patients with progressive mCRPC, with 46.9% achieving ≥50% PSA decline (34.4% confirmed) and 59.1% exhibiting circulating tumor cell control, alongside a manageable safety profile (Tagawa et al., 2024).